MedTrace Logo

JKN2306 in Healthy Subjects: Single Ascending Dose and Food Effect Study

NCT07412938 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-02-17

No results posted yet for this study

Summary

This first-in-human, single-center study in China evaluated the safety, tolerability, and pharmacokinetics of single oral doses of JKN2306 tablets in healthy adult subjects and assessed the effect of a high-fat, high-calorie meal on the pharmacokinetics of JKN2306.

Conditions

  • Acute Pain

Interventions

DRUG

JKN2306

JKN2306 tablet, oral

DRUG

Placebo

matching placebo tablet

Sponsors & Collaborators

  • Joincare Pharmaceutical Group Industry Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-12
Primary Completion
2025-07-02
Completion
2025-07-02

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07412938 on ClinicalTrials.gov